A 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ [hydrochlorothiazide], 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome.
Phase of Trial: Phase III
Latest Information Update: 07 May 2017
At a glance
- Drugs Losartan (Primary) ; Losartan/hydrochlorothiazide (Primary)
- Indications Hypertension; Metabolic syndrome
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 24 Jun 2009 Actual patient number changed from 1614 to 1738 as reported by ClinicalTrials.gov.
- 05 Nov 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.